Oliver Hill

1.3k total citations
15 papers, 419 citations indexed

About

Oliver Hill is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Oliver Hill has authored 15 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 8 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Oliver Hill's work include Immune Cell Function and Interaction (5 papers), Cell death mechanisms and regulation (4 papers) and CAR-T cell therapy research (3 papers). Oliver Hill is often cited by papers focused on Immune Cell Function and Interaction (5 papers), Cell death mechanisms and regulation (4 papers) and CAR-T cell therapy research (3 papers). Oliver Hill collaborates with scholars based in Germany, United States and United Kingdom. Oliver Hill's co-authors include Christian Gieffers, Christian J. Merz, Jaromir Sykora, Harald Fricke, Meinolf Thiemann, David M. Richards, Michael Kluge, Cornelia Monzel, Amelie Heuer‐Jungemann and Tim Liedl and has published in prestigious journals such as The Journal of Experimental Medicine, Cancer Research and Small.

In The Last Decade

Oliver Hill

15 papers receiving 407 citations

Peers

Oliver Hill

IMMUN

ONCOL

RNMI

Nate N. Waldron United States

Martin Siegemund Germany

Sharon Yang United States

Jeomil Bae South Korea

Szilvia Désaknai Hungary

Iris Mildenberger Germany

Agnė Petrošiūtė United States

Jonathan Lerner United States

Marie Laviron France

Caitlin M. Sorensen United States

Nate N. Waldron United States

Oliver Hill

135 ×0.6

121 ×0.6

IMMUN

214 ×1.6

ONCOL

34 ×0.9

RNMI

32 ×0.9

Citations per year, relative to Oliver Hill Oliver Hill (= 1×) peers Nate N. Waldron

Countries citing papers authored by Oliver Hill

Since Specialization

Citations

This map shows the geographic impact of Oliver Hill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Hill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Hill more than expected).

Fields of papers citing papers by Oliver Hill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Hill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Hill. The network helps show where Oliver Hill may publish in the future.

Co-authorship network of co-authors of Oliver Hill

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Hill. A scholar is included among the top collaborators of Oliver Hill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Hill. Oliver Hill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Frankish, Jamie, Debayan Mukherjee, Erminia Romano, et al.. (2023). The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy. Frontiers in Immunology. 14. 1160116–1160116. 11 indexed citations

Berger, Ricarda, Oliver Hill, Tim Liedl, et al.. (2021). Nanoscale FasL Organization on DNA Origami to Decipher Apoptosis Signal Activation in Cells. Small. 17(26). e2101678–e2101678. 59 indexed citations

Richards, David M., Viola Marschall, Christian J. Merz, et al.. (2019). HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality. Journal for ImmunoTherapy of Cancer. 7(1). 191–191. 24 indexed citations

Richards, David M., et al.. (2019). Concepts for agonistic targeting of CD40 in immuno-oncology. Human Vaccines & Immunotherapeutics. 16(2). 377–387. 53 indexed citations

Merz, Christian J., Jaromir Sykora, Viola Marschall, et al.. (2018). The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell–mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells. Journal of Immunotherapy. 41(9). 385–398. 21 indexed citations

Legler, Karen, Charlotte A. E. Hauser, Jan‐Hen drik Egberts, et al.. (2018). The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. Cell Death and Disease. 9(5). 445–445. 33 indexed citations

Thiemann, Meinolf, David M. Richards, Michael Kluge, et al.. (2018). A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity. Frontiers in Oncology. 8. 387–387. 17 indexed citations

Thiemann, Meinolf, Jaromir Sykora, David M. Richards, et al.. (2018). Abstract 3754: The novel hexavalent human CD137/4-1BB agonist HERA-CD137L promotes anti-cancer immunity by activating CD8 T cells while regulatory T cells are not affected. Cancer Research. 78(13_Supplement). 3754–3754. 1 indexed citations

Fleten, Karianne G., Viví Ann Flørenes, Lina Prasmickaite, et al.. (2016). hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma. Cell Death Discovery. 2(1). 16081–16081. 10 indexed citations

10.

Merz, Christian J., Jaromir Sykora, Oliver Hill, et al.. (2015). Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. Anti-Cancer Drugs. 26(7). 716–727. 20 indexed citations

11.

Teodorczyk, Marcin, Susanne Kleber, Damian Wollny, et al.. (2015). CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Cell Death and Differentiation. 22(7). 1192–1202. 43 indexed citations

12.

Gao, Liang, Dávid Brenner, Enric Llorens-Bobadilla, et al.. (2015). Infiltration of circulating myeloid cells through CD95L contributes to neurodegeneration in mice. The Journal of Experimental Medicine. 212(4). 469–480. 30 indexed citations

13.

Gieffers, Christian, Michael Kluge, Christian J. Merz, et al.. (2013). APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fcγ Receptors. Molecular Cancer Therapeutics. 12(12). 2735–2747. 94 indexed citations

14.

Gieffers, Christian, Michael Kluge, Oliver Hill, et al.. (2011). Abstract LB-232: APG350, a dimerized single chain TRAIL receptor agonist with enhanced functional properties. Cancer Research. 71(8_Supplement). LB–232. 1 indexed citations

15.

Hill, Oliver, et al.. (1978). Microbial-Like Antigens in Human Leukemia. Oncology. 35(6). 263–266. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact